357 related articles for article (PubMed ID: 17512720)
1. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
Duffy MJ; van Dalen A; Haglund C; Hansson L; Holinski-Feder E; Klapdor R; Lamerz R; Peltomaki P; Sturgeon C; Topolcan O
Eur J Cancer; 2007 Jun; 43(9):1348-60. PubMed ID: 17512720
[TBL] [Abstract][Full Text] [Related]
2. Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance.
Popat S; Wort R; Houlston RS
BMC Cancer; 2006 Jun; 6():150. PubMed ID: 16753067
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
4. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
5. Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy.
Graziano F; Catalano V; Baldelli AM; Cascinu S
Expert Rev Anticancer Ther; 2001 Aug; 1(2):247-57. PubMed ID: 12113030
[TBL] [Abstract][Full Text] [Related]
6. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676
[TBL] [Abstract][Full Text] [Related]
7. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer.
Japink D; Leers MP; Sosef MN; Nap M
Anticancer Res; 2009 Aug; 29(8):3245-51. PubMed ID: 19661342
[TBL] [Abstract][Full Text] [Related]
8. Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients.
El-Awady S; Lithy R; Morshed M; Khafagy W; Abd Monem H; Waleed O; Badr S; Fekry A; El Nakeeb A; Ghazy H; El Yamany M; Metwally T; El-Arman M; Farid M
Hepatogastroenterology; 2009; 56(90):361-6. PubMed ID: 19579599
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
[TBL] [Abstract][Full Text] [Related]
10. [Serological markers of colorectal cancer].
Nielsen HJ; Christensen IJ; Brünner NA
Ugeskr Laeger; 2005 Oct; 167(44):4163-7. PubMed ID: 16266568
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
[TBL] [Abstract][Full Text] [Related]
12. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.
Saw RP; Koorey D; Painter D; Gallagher PJ; Solomon MJ
Br J Surg; 2002 Nov; 89(11):1409-15. PubMed ID: 12390383
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive molecular markers in colorectal carcinoma.
Bendardaf R; Lamlum H; Pyrhönen S
Anticancer Res; 2004; 24(4):2519-30. PubMed ID: 15330208
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive testing for colorectal cancer: a review.
Ouyang DL; Chen JJ; Getzenberg RH; Schoen RE
Am J Gastroenterol; 2005 Jun; 100(6):1393-403. PubMed ID: 15929776
[TBL] [Abstract][Full Text] [Related]
15. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
16. Faecal screening of colorectal cancer.
Loganayagam A
Int J Clin Pract; 2008 Mar; 62(3):454-9. PubMed ID: 17887994
[TBL] [Abstract][Full Text] [Related]
17. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance after resection.
Søreide K; Slewa A; Stokkeland PJ; van Diermen B; Janssen EA; Søreide JA; Baak JP; Kørner H
Cancer; 2009 Jan; 115(2):271-82. PubMed ID: 19109816
[TBL] [Abstract][Full Text] [Related]
19. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
20. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.
Møller Sørensen N; Vejgaard Sørensen I; Ørnbjerg Würtz S; Schrohl AS; Dowell B; Davis G; Jarle Christensen I; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(7):774-86. PubMed ID: 18584515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]